Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Itvisma

Cell and Gene Therapy Today

Cell and Gene Therapy Today—July 9, 2026

This week’s Gene and Cell Therapy update highlights regulatory progress,…

Neuroscience Today

Neuroscience Today—July 8, 2026

This week’s Neuroscience update highlights regulatory progress, advancing…

Neuroscience

Neuroscience Today—April 29, 2026

This week’s Neuroscience update highlights regulatory actions, clinical…

by Ruairi McEntee

Rare Disease news

Rare Disease Today—November 27, 2025

This week’s rare diseases update spotlights key developments, regulatory…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
LucidScope AI Audit Analyses
Public Health News
Monthly Strategic Roundups
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Neuroscience Strategic Roundup | June17–July 21, 2026
AdaptHealth Diabetes Health Divestiture to Cardinal Health | Lucid Diligence Brief
Endocrinology Strategic Roundup | June 23–July 20, 2026
AI perception of JAK Inhibitors in Atopic Dermatitis | LucidScope AI Visibility Audit
Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief

Tags

AAN 2025 Affinia Therapeutics Aqvesme ATTRR-CM Beta Thalassemia Bone mineral density biomarkers brain mapping Brain Tumor Brepocitinib cardiac care Cardiac Surgery Clinical Clinical Data Visibility Curant Rare Dynavax Estrogen Receptor-Positive Breast Cancer Ethicon Exergame Rehabilitation FDA review FibroGen Forxiga Galvanic Health Gazyva health IT strategy HIV prevention Lasmiditan Lexicon Pharma Lumateperone malaria treatment mRNA-3927 MRSA pediatric rare diseases Pediatric Vaccine Pharmac New Zealand Polio Vaccines pulmonology radioligand therapy Repatha S-606001 SK Bioscience Systemic psoriasis Sézary syndrome Tactical Intelligence Tezepelumab Universal Influenza Vaccine

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Neuroscience Strategic Roundup | June17–July 21, 2026
AdaptHealth Diabetes Health Divestiture to Cardinal Health | Lucid Diligence Brief
Endocrinology Strategic Roundup | June 23–July 20, 2026
AI perception of JAK Inhibitors in Atopic Dermatitis | LucidScope AI Visibility Audit
Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief

TAGS

AAN 2025 Affinia Therapeutics Aqvesme ATTRR-CM Beta Thalassemia Bone mineral density biomarkers brain mapping Brain Tumor Brepocitinib cardiac care Cardiac Surgery Clinical Clinical Data Visibility Curant Rare Dynavax Estrogen Receptor-Positive Breast Cancer Ethicon Exergame Rehabilitation FDA review FibroGen Forxiga Galvanic Health Gazyva health IT strategy HIV prevention Lasmiditan Lexicon Pharma Lumateperone malaria treatment mRNA-3927 MRSA pediatric rare diseases Pediatric Vaccine Pharmac New Zealand Polio Vaccines pulmonology radioligand therapy Repatha S-606001 SK Bioscience Systemic psoriasis Sézary syndrome Tactical Intelligence Tezepelumab Universal Influenza Vaccine

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy